Innovative Heart Disease Treatments

 TAVI stands for transcatheter aortic valve implantation.

TAVI is a minimally invasive technique that includes inserting a new aortic valve through a catheter inside the damaged valve. Aortic stenosis, a condition in which the aortic valve narrows and reduces blood flow from the heart to the rest of the body, is commonly treated using TAVI. Due to its less invasive nature and ability to be carried out under local anesthesia, TAVI has grown in popularity in recent years. Interventional cardiologist Cardiologist suggests TAVI to his patients who are poor surgical candidates.

Left Ventricular Assist Device  

A surgically inserted device called an LVAD improves the heart's ability to pump blood. Patients with severe heart failure who are awaiting a heart transplantor who are not strong candidates for one are treated with the LVAD. Blood from the left ventricle is taken and pumped into the aorta by the LVAD, bypassing the frail heart muscle. The patient wears an external battery pack around their waist to power the device.

                                    

 Mitral Clip

The mitral valve, which is situated between the left atrium and left ventricle of the heart, is repaired with a device called a Mitra Clip. A tiny incision in the groin is used to guide a catheter, which is used to insert the device, to the heart. The mitral valve's leaflets are clipped together after the device is in position, which lessens the volume of blood that travels backwards through the valve. Mitral regurgitation, a disease in which blood flows back into the left atrium rather than forward into the left ventricle, is treated using the Mitra Clip.

Uses of genes

Delivering healthy genes to the heart to replace or repair damaged genes is a potential new approach to treating heart disease. Restoring the heart's natural function and lowering the risk of heart failure are the two objectives of gene therapy. Although gene therapy is still in its infancy, investigations in animal models and human clinical trials have yielded encouraging results.

To know more information visit https://www.cardiology.scientexconference.com/.

Comments

Post a Comment

Popular posts from this blog

Image
  Ventricular Assist Device – Miniature The treatment of individuals with severe heart failure has been transformed by the development of a ventricular assist device (VAD). When a donor heart cannot be identified, the VAD, which was initially designed as a bridge to transplantation , has been proved to extend life and improve quality of life. Older models needed patients to ambulate with hefty , huge external batteries and control devices and required the implantation of a big pump. Yet in the upcoming years, a number of ground-breaking advancements in device size , battery life, and even wireless charging technologies may render these devices physically undetectable and possibly reduce patient vulnerability to infections. The rates of haemolysis, thrombosis, and secondary aortic valve insufficiency have also been constrained by numerous mechanical improvements and newer operating paradigms. Cardiac Decellularization and Engineered Heart Tissue Promising new direction...
Read more
Image
Myocardial infarction events involving morality, incredibly high temperatures, and minute particles.  Myocardial infarction (MI) morbidity has been connected to extreme temperature events (ETEs), such as heat wave and cold spell, but their effects on MI mortality are less well understood. Although ambient fine particulate matter (PM2.5) and severe temperatures may work in concert to increase cardiovascular mortality , it is still unclear whether or how ETEs and PM2.5 interact to cause MI deaths.METHODS: To examine the relationship between exposure to ETEs and PM2.5 and MI mortality and assess their interacting effects, a time-stratified case-crossover study of 202 678 MI deaths in Jiangsu province, China, from 2015 to 2020 was conducted. Twelve ETE definitions were created using a variety of temperature thresholds and durations based on the perceived ambient temperature. In order to estimate daily ETEs and PM2.5exposures , values were taken from validated grid datasets at reside...
Read more

New Drug Nearly Eradicates “Stealth” Cholesterol (Lp(a)) – A Game‑Changer in Heart Disease Prevention

Image
A recent clinical trial reported in the New England Journal of Medicine and showcased at the American College of Cardiology revealed that lepodisiran—an experimental RNA-targeting drug—can reduce lipoprotein(a) [Lp(a)] by nearly 100% after a single dose, with sustained effects over a year 🔍 What You Need to Know Lp(a) is a genetically determined, stealth cholesterol that significantly raises the risk of heart attacks and strokes yet is not addressed by diet or standard statins. The Phase 2 trial, involving 320 participants across 10 countries, showed almost total Lp(a) suppression at 6 months, maintained at 1 year. Reported side effects were mild, primarily limited to injection-site reactions. No serious safety issues were found.                      🌍 Why This Matters This breakthrough could pave the way for targeted Lp(a) therapies—potentially reducing cardiovascular risk in over 1.4 billion people globally with elevated levels....
Read more